Abstract
Tumor tissues were clearly visualized in scintigrams of experimental animals bearing tumors a few hours after the administration of the $^{99m}$Tc complex of ethylenediamine-$N,N$-diacetic acid ($^{99m}$Tc-EDDA). The study utilized a wide range of animal models, including mice bearing Ehrlich tumors, Sarcoma 180, and spontaneous mammary carcinomas, as well as rats with metastatic fibrosarcomas. In the Ehrlich tumor model, radioactivity ratios for tumor-to-blood and tumor-to-muscle reached 3.32 and 7.96, respectively, at 3 hours post-administration, demonstrating high imaging contrast.
Introduction
In the early 1980s, nuclear medicine primarily utilized tracers such as Gallium-67 ($^{67}$Ga) and Thallium-201 ($^{201}$Tl) for tumor localization. Despite their effectiveness, these isotopes presented challenges including long half-lives, slow blood clearance, and limited availability. Technetium-99m ($^{99m}$Tc) emerged as the preferred isotope due to its ideal gamma energy, 6-hour half-life, and ease of on-site production. This research explores the potential of ethylenediamine-$N,N$-diacetic acid (EDDA), an amino acid derivative, as a ligand to carry $^{99m}$Tc specifically to tumor cells.
Methods and Materials
The researchers synthesized the $^{99m}$Tc-EDDA complex using stannous chloride (SnCl$_2$) as a reducing agent. The agent's performance was evaluated across several dimensions:
- Biological Models: A diverse battery of tumors was tested, including Ehrlich ascites tumors, Sarcoma 180, homotransplantable lymphoma (hamsters), MC-induced fibrosarcomas (rats), and spontaneous mammary carcinomas (mice).
- Scintigraphy: Animals were scanned using a scintillation camera with a pinhole collimator at intervals ranging from 20 minutes to 5.5 hours post-injection.
- Biodistribution: Radioactivity levels in various organs (blood, muscle, liver, kidneys) were measured at 1 and 3 hours to quantify uptake ratios.
- Toxicity: Acute toxicity tests were performed in mice with doses up to 1200 mg/kg.
Results and Discussion
Scintigraphic Visualization and Timing
Tumors became clearly visible on scintigrams within 1 to 1.5 hours post-injection. The time-course study revealed that while the tracer initially distributed throughout the body, it cleared rapidly from the blood and non-target tissues, primarily through the kidneys.
Contrast and Specificity
By 3 hours post-injection, the contrast between the tumor and surrounding tissues was significantly enhanced. The rapid renal clearance resulted in low background "noise," although the kidneys themselves remained prominent in the images.
An important finding regarding specificity was the tracer's behavior in inflammatory sites. While $^{99m}$Tc-EDDA initially accumulated in induced abscesses and inflammation, this signal faded quickly compared to the persistent signal in tumor tissues. This temporal difference suggests a potential method for differentiating malignancy from infection.
Safety and Mechanism
Toxicity studies indicated a high safety margin, with no deaths observed at doses 3600 times higher than the projected human clinical dose. Interestingly, unlike typical amino acid tracers, $^{99m}$Tc-EDDA did not show high uptake in the pancreas, suggesting a unique mechanism of tumor accumulation that does not follow standard protein synthesis pathways.
Conclusion
$^{99m}$Tc-EDDA demonstrates significant promise as a tumor-seeking radiopharmaceutical, offering high contrast, rapid clearance, and excellent safety. However, its primary excretion through the kidneys may mask tumors in the lower abdomen. Future work is required to fully elucidate the biochemical mechanism of its tumor uptake and to compare its clinical efficacy directly against established agents like $^{67}$Ga.
Summary updated